Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Subscribe To Our Newsletter & Stay Updated
